ALZ-NET International

The collection of Real-World Data (RWD) globally is integral to the discovery, evaluation and evolution of novel avenues for the diagnosis, prevention, treatment and care of Alzheimer’s and other dementia. In addition, RWD can play a key role in the identification and understanding of health disparities, and the subsequent development and implementation of initiatives to advance health equity.

ALZ-NET International is a global forum to connect ALZ-NET with RWD platforms related to Alzheimer’s and dementia from around the world. With the common goal of aligning and accelerating progress globally, ALZ-NET International members share their experiences, ideas and outputs to inform infrastructure development, enable innovation and disseminate findings to the field.

ALZ-NET International partners

ALZ-NET International partners listed have entered into a memorandum of understanding (MOU) with ALZ-NET to facilitate the mutual exchange of scientific information, allowing for functional comparisons of the platforms. Partners are encouraged to share scientific expertise openly with other ALZ-NET International partners and to seek additional opportunities for collaboration with the Alzheimer’s Association and other ALZ-NET International partners.

Australia
ADNeT Registry

The Australian Dementia Network Registry: RWD Therapy Surveillance Program (“ADNeT Registry”) is a voluntary health care provider-enrolled patient network that collects clinical and safety data for patients treated with newly approved Alzheimer’s disease therapies intended to track the long-term health outcomes associated with their use in real-world settings in Australia.

The Netherlands
ABOARD Cohort

The ABOARD Cohort, part of the overarching ABOARD project, a public-private initiative with over 30 partners, aims to involve as many Dutch citizens as possible in Alzheimer’s research. This study, which is considered a societal initiative with participant initiated enrollment from a governance perspective, aims to collect real-world data across the entire Alzheimer spectrum, i.e. from at-risk to dementia. Data collection focuses on medical record data, patient reported outcomes on perceived health, and linkage with external data sources.

Republic of Korea
JOY-ALZ

The Korean Dementia Association is the sponsor of the Korean JOint registrY for ALZheimer's treatment and diagnostics (“JOY-ALZ”), a voluntary health care provider-enrolled patient network that collects clinical and safety data for patients treated with newly approved Alzheimer’s disease therapies intended to track the long-term health outcomes associated with their use in real-world settings in South Korea.

Funding opportunities

Alzheimer’s Association Funding Program for Global Real-World Data Platforms (ALZ-RWD)

Status: Accepting Pre-Applications
Learn more about this grant

Real-World Data (RWD) platforms house data on patient health status and health care collected within real-world settings and are essential to inform and improve care in the rapidly evolving AD treatment landscape. To build on the global momentum in this field, the Alzheimer’s Association has launched a peer-reviewed funding program to support the advancement of and opportunities of global RWD initiatives. Applications are expected to augment and accelerate global initiatives with the goal of developing, expanding and aligning RWD platforms’ infrastructure, data and impact.

This grant is open to international (non-U.S.) applications.